Solu Cortef

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solu Cortef

Property Description
Active Ingredient Hydrocortisone sodium succinate
Form Sterile powder for injection (Intravenous or Intramuscular)
Pharmacological Class Glucocorticoid (Corticosteroid)
Common Use Emergency treatment requiring rapid, high-dose steroid therapy
Origin Synthetic analog of the adrenal hormone, cortisol

Solu-Cortef is the brand name for the injectable medication hydrocortisone sodium succinate, which is classified as a potent glucocorticoid. This medication is manufactured by Pfizer Inc. and is dispensed as a prescription-only (Rx) medicine. It is supplied as a sterile powder, which is combined with a liquid diluent immediately prior to administration, often using a proprietary ACT-O-VIAL system designed for emergency use.

The medication's distinguishing feature is its high water-solubility. This chemical property permits the immediate administration of high doses of hydrocortisone directly into a vein, ensuring the active ingredient reaches peak blood concentrations almost instantly. This rapid onset of action is crucial for treating acute, life-threatening conditions.

Hydrocortisone sodium succinate is categorized as an anti-inflammatory glucocorticoid used to modify the body's immune response. This means the medicine is specifically formulated to quickly calm severe inflammation and reduce harmful immune or allergic activity throughout the body.

The swift action of Solu-Cortef is vital for managing critical medical events, such as acute adrenal insufficiency (adrenal crisis), a severe lack of cortisol where immediate hormone replacement is necessary to stabilize the patient.

Regulatory References

  1. NIH DailyMed label
  2. NIH DailyMed Label

What side effects are possible with Solu Cortef?

Possible Side Effects and Safety Information

Hydrocortisone sodium succinate, the active ingredient in Solu-Cortef, is associated with a safety profile that reflects the systemic nature of glucocorticoids, with effects classified across multiple System-Organ Classes (SOC) in regulatory documents.

Adverse effects are documented in domains including Endocrine Disorders (e.g., HPA axis suppression), Metabolism and Nutrition Disorders (e.g., fluid retention, hypokalemic alkalosis), Psychiatric Disorders (e.g., mood swings, insomnia), and Gastrointestinal Disorders.

Serious Adverse Reactions and Key Concerns

The official safety documents identify certain adverse reactions as serious. These include anaphylaxis (documented as rare), severe and potentially fatal infections (including opportunistic types), and peptic ulcer with possible perforation and hemorrhage. Other documented serious events include cardiac arrest, myocardial rupture (following recent MI), and pheochromocytoma crisis.

Exposure-Related Safety Patterns

The risk of many complications is explicitly linked to the duration of use. Effects such as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, osteoporosis, and the formation of cataracts/glaucoma are primarily associated with prolonged or chronic therapy. Conversely, a temporary burning or tingling sensation in the perineal area is sometimes noted immediately following intravenous injection.

Population and Contraindication Notes

The medication is contraindicated in patients with a known systemic fungal infection and in those with known hypersensitivity to the drug or its components. Specific safety statements exist for special populations, including the necessity for monitoring growth and development in pediatric patients and the required caution in patients with hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This section describes the official regulatory guidance on managing an overdose situation involving Solu Cortef (hydrocortisone sodium succinate).

When to Seek Immediate Medical Help

If an overdose is suspected, it is critical to call a poison control center or seek immediate medical care right away. Timely action is required in a suspected overdose scenario.

Documented Overdose Scenarios

Official labeling addresses two types of potential overdose from corticosteroid use:

  • Acute Overdosage: This refers to a sudden overexposure.
  • Chronic Overdosage: This is generally considered in the context of long-term use for severe disease that requires continuous steroid therapy.

Overdose Management Statements

The required actions for managing overexposure are outlined by regulatory documents:

  • Acute Management: Treatment for an acute overdosage is by supportive and symptomatic therapy. This means focusing on the patient's immediate comfort and clinical stability.
  • Chronic Management: In cases of chronic overdosage, particularly when managing a severe underlying disease, the corticosteroid dosage may be temporarily reduced, or an alternate-day treatment schedule may be introduced. The presence of a severe condition requiring continuous therapy constrains how aggressively the dose can be reduced.

The regulatory documentation clearly mandates seeking immediate professional medical assistance upon suspecting any type of overdose. The official profile for this drug’s overexposure is defined by the acute and chronic classifications, guiding the initial response.

Therapeutic Uses of Solu Cortef

What Solu-Cortef Treats: Main Uses and Benefits

Solu-Cortef is an injectable glucocorticoid generally applied in conditions considered relevant for short-term symptomatic assistance during acute, severe, or disruptive episodes. The therapeutic assistance is commonly used for managing symptoms associated with a critical period across several core domains.

The medication is relevant for easing symptoms in conditions such as acute adrenocortical insufficiency (adrenal crisis), severe allergic reactions including anaphylaxis, critical asthma exacerbations, and acute flare-ups of systemic inflammatory diseases like ulcerative colitis and rheumatoid arthritis. This provides the benefit of symptomatic relief by helping to moderate severe inflammation and systemic imbalance that interfere with daily functioning.

“The injection is relevant for easing symptoms that become acute and disruptive, which arise from overwhelming allergic or immune responses.”

In clinical scenarios, its primary role is to support the patient during a crisis by easing acute systemic distress, thereby contributing to the process of stabilizing vital functions. It is commonly used when supportive symptom management is appropriate due to temporary physiological imbalance.

Quick Fact: Relief for Severe Systemic Inflammation

The therapeutic goal is to address symptom clusters that may become intense or disruptive due to an overwhelming immune or inflammatory response.

Eligibility and Restrictions for Use

The use of Solu-Cortef (hydrocortisone sodium succinate) is strictly defined by regulatory eligibility rules concerning infectious status, age, administration route, and pre-existing conditions.

Populations For Whom Use Is Contraindicated

Category Official Regulatory Statement
Infectious Status Patients with systemic fungal infections must not use the medicine.
Hypersensitivity Patients with a known allergy to hydrocortisone sodium succinate or any component of the product.
Vaccination Status Patients receiving immunosuppressive doses must not receive live or live-attenuated vaccines.

Eligibility Restrictions and Cautions

Category Official Regulatory Statement
Administration Route The medicine is contraindicated for intrathecal and epidural administration.
Pediatric Eligibility Formulations containing benzyl alcohol are contraindicated for use in premature infants.
Comorbidity-Based Use Use requires caution in patients with conditions like congestive heart failure, hypertension, renal insufficiency, or peptic ulcer disease.
Reproductive Status Use during pregnancy requires that the potential maternal benefit outweigh the potential fetal hazard; infants should be observed for signs of hypoadrenalism.

Connection to the overall eligibility profile:

Regulatory documents define who can and cannot use the medicine by establishing clear categories of contraindication based on infectious status and route of administration, alongside definitive restrictions for pediatric age groups and co-existing conditions that require specific clinical caution.

What should I know about interactions with other medicines?

Solu Cortef (hydrocortisone sodium succinate) can interact with a variety of other medicines, primarily through metabolic pathways and additive pharmacodynamic effects. These interactions may necessitate a change in dosage or close medical monitoring.

Major Interacting Medicine Categories

Interaction Type Interacting Products (Examples) Effect on Solu Cortef or Patient Safety
Enzyme Inducers Phenytoin, Rifampin, Carbamazepine, Barbiturates May increase Solu Cortef's metabolism, potentially requiring a dose increase to maintain clinical effect.
Enzyme Inhibitors Ketoconazole, Estrogens (including Oral Contraceptives) May decrease Solu Cortef's metabolism, potentially increasing its effects and the risk of adverse events.
Potassium-Depleting Agents Diuretics, Amphotericin B injection May enhance the risk of developing hypokalemia (low potassium).
Anticoagulants Warfarin Coagulation indices require frequent monitoring as the effect of anticoagulants may be altered.
Anticholinesterases Neostigmine, Pyridostigmine Concomitant use in patients with myasthenia gravis may result in severe weakness; withdrawal of anticholinesterases is advised before initiating therapy.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Aspirin (concomitant use) May increase the risk of gastrointestinal bleeding and ulceration.

Other Interaction Constraints

  • Vaccines: Administration of live or live-attenuated vaccines is contraindicated during treatment with immunosuppressive doses of Solu Cortef. Killed or inactivated vaccines may be administered, but the immune response may be diminished.
  • Blood Glucose: Corticosteroids can increase blood glucose levels, potentially requiring adjustments to antidiabetic medicines.
  • Procedural: Solu Cortef is generally not to be diluted or mixed with other solutions for parenteral administration due to potential physical incompatibilities.

Mechanism of Action

Genomic Repression of Pro-Inflammatory Genes

Hydrocortisone acts as an agonist at the intracellular Glucocorticoid Receptor ( GR), which is followed by the drug-receptor complex translocating to the cell nucleus. The primary, sustained action involves directly repressing the activity of transcription factors like Nuclear factor kappa B ( NF-kappa B). This interference switches off the genetic instructions for producing inflammatory chemicals ( cytokines and prostaglandins), leading to systemic reduction in signaling pathways associated with immune and inflammatory responses.


Non-Genomic Action and Vascular Permissive Effects

Rapid-onset actions are independent of gene expression, involving the modulation of cell membranes and signal transduction pathways by high concentrations of hydrocortisone. This non-genomic action involves rapid modulation of cell membrane properties and a reduction in mediator release (such as histamine) that influence vascular permeability. Furthermore, the drug exerts a permissive effect on catecholamines, enhancing the responsiveness of blood vessels to hormones that maintain pressure. This contributes to the regulation of physiological responses, particularly within the circulatory system.


Metabolic Modulation and Immune Cell Trafficking

The mechanism extends to metabolic function by activating specific Glucocorticoid Response Elements ( GREs) to increase the synthesis of gluconeogenic enzymes in the liver, leading to increased glucose production. Additionally, the drug suppresses the function and alters the distribution of immune cells like T-lymphocytes and macrophages, influencing substrate availability and contributing to the redistribution and functional modulation of cells within immune pathways.

Dosage and Administration Information

Official Administration Guidelines for Solu-Cortef

Solu-Cortef (hydrocortisone sodium succinate) is administered as a high-dose, short-term treatment, and its use is guided by specific preparation and frequency rules.


Administration Scope

Feature Official Instruction
Route of Administration Intravenous (IV) injection or Intramuscular (IM) injection; IV is the preferred initial method.
Adult Dosing Schedule Initial Dose: 100 mg to 500 mg or more. This dose may be repeated at 2, 4, or 6 hour intervals as determined by clinical status.
Preparation requirements The sterile powder must be reconstituted with a suitable diluent, such as Bacteriostatic Water for Injection, prior to administration.
Pediatric Administration Rules Dosing is governed by the severity of the condition rather than body weight alone. The initial dose should generally not be less than 25 mg daily.
Special Procedural Conditions The IV injection should be administered slowly, generally over a period of 30 seconds up to 10 minutes for larger doses.

Use Protocol Structure

Official step sequence:

  • The powder is reconstituted with the specified diluent and inspected for clarity.
  • The solution is administered via IV injection (slowly) or IM injection.
  • The treatment is typically limited to 48 to 72 hours; for prolonged use, the dose must be gradually reduced (tapered) or transitioned to an oral form.

This protocol defines the medication as an intermittent-use parenteral therapy for acute, non-oral use, ensuring the rapid delivery required by the drug's properties and establishing mandatory limits on the duration of high-dose treatment.

Recent Clinical Evidence

Overview of Clinical Trials

The active compound in Solu Cortef, hydrocortisone sodium succinate, is the injectable form of the naturally occurring glucocorticoid, hydrocortisone. Research investigated the medication’s activity profile, particularly its anti-inflammatory and immunosuppressive properties, which are utilized across various indications.

Studies have been conducted to evaluate the treatment’s effect in conditions related to joint mobility, pain perception, and endocrine disorders, where it is used as replacement therapy for adrenocortical insufficiency.

Core Data

Clinical trials, including randomized studies, explore the treatment's activity in the context of acute episodes, such as severe asthma exacerbations, allergic states, and acute adrenocortical insufficiency. The highly water-soluble nature of the compound permits rapid intravenous administration, with demonstrable effects typically evident within one hour of injection. Research has also examined the treatment’s effect on surrogate markers of inflammation in study participants.

Newer research continues to evaluate alternative administration methods and formulations. For instance, studies have explored the effect of continuous subcutaneous hydrocortisone infusion (CSHI) in patients with conditions like Congenital Adrenal Hyperplasia (CAH) or Addison's disease, showing positive activity on adrenal steroid control and quality of life measures in some participants.

Risk Documentation

The safety profile is continually monitored in clinical settings and trials. Studies document common adverse events, which often include headache, gastrointestinal upset, and fatigue. Serious adverse events, though rare, involve reactions such as allergic response or liver enzyme elevation.

Study Limitations

Studies documented information regarding potential interactions with certain drugs metabolized by the CYP3A4 enzyme, requiring professional review to avoid risk. Additionally, limitations were noted regarding its use in individuals with severe kidney impairment.

Frequently Asked Questions (FAQ)

Common questions about Solu Cortef (FAQ)


Q: How long does the effect of Solu Cortef last?

A: Regulatory documents indicate that after an intravenous injection, the beneficial effects typically become noticeable within one hour. The active ingredient remains in the body for a variable period, with near complete excretion usually occurring within 12 hours. If a constant, high level of the medication is needed, official administration guidelines indicate the injection may be repeated every 4 to 6 hours.


Q: Why is it important to carry Solu Cortef if I have adrenal insufficiency?

A: Solu Cortef is an injectable form of the hormone cortisol, and it is used as a rapid replacement therapy. For people with adrenal insufficiency, patient education materials emphasize the importance of having an emergency injection kit available for situations like severe injury, persistent vomiting, or when they are too ill to take their daily oral medication. This is intended to quickly provide replacement hormones during a critical event.


Q: Is there any information about Solu Cortef use during pregnancy?

A: Official information states that the use of Solu Cortef during pregnancy requires that the potential benefit to the mother must be determined to outweigh any potential risk to the fetus. If the medication is used during pregnancy, regulatory guidelines state that the newborn infant must be monitored for signs of hypoadrenalism, which is a potential hormone deficiency.


Q: Is it possible for Solu Cortef to cause an allergic reaction itself?

A: Yes, it is possible for the medication to cause an allergic reaction. Official documents list hypersensitivity reactions, including the severe and potentially life-threatening reaction known as anaphylaxis, among the reported adverse events. The drug is also contraindicated in patients with a known allergy to the active ingredient or any other component, as indicated in official documentation.


Q: Is it common to feel jittery or anxious after a Solu Cortef injection?

A: The official documentation for corticosteroids lists changes in mood and mental state as potential side effects. These psychiatric disturbances can include symptoms such as anxiety, restlessness, and insomnia (difficulty sleeping), which are patient terms for feelings commonly experienced.


Q: What is the difference between Solu Cortef and methylprednisolone?

A: Solu Cortef and methylprednisolone are both different types of injectable corticosteroids. Regulatory documents point out that they have different potencies and different effects on sodium retention in the body. For instance, methylprednisolone causes very little sodium retention, unlike hydrocortisone. These differences in properties are noted in official documents when considering high-dose therapy.


Q: What does 'systemic corticosteroid' mean in relation to Solu Cortef?

A: Solu Cortef is classified as a 'systemic' medication because it is designed to work throughout the entire body, affecting multiple organ systems. Official documents describe it as an anti-inflammatory glucocorticoid that is quickly distributed after injection to modify the body’s overall immune and metabolic responses, rather than only treating one specific, localized area.


Q: Can older adults be treated with Solu Cortef?

A: Official documents do not generally prohibit the use of the medicine in older adults based solely on age. However, they advise that caution is needed in patients who may have common age-related conditions, such as congestive heart failure, high blood pressure (hypertension), or issues with kidney function (renal insufficiency).


Q: Are there different strengths or concentrations of Solu Cortef?

A: Yes, official product information indicates that Solu Cortef Sterile Powder is manufactured in multiple standard strengths. These concentrations typically include 100 mg, 250 mg, 500 mg, and 1000 mg vials to meet different clinical needs.


Q: What is the role of Solu Cortef in treating severe asthma?

A: Official guidelines indicate that Solu Cortef is used for the management of severe or debilitating bronchial asthma. It is prescribed for acute episodes where the condition does not respond adequately to conventional treatments. The medication is intended to quickly reduce severe inflammation and modify the related immune response.


Q: Does Solu Cortef treat the cause of a disease or just the symptoms?

A: As an anti-inflammatory glucocorticoid, Solu Cortef works to modify the body’s inflammatory and immune responses. In inflammatory conditions, it is generally used to suppress symptoms and disease activity by modifying the body's response. However, in cases of severe hormone deficiency, such as acute adrenal crisis, it acts as essential hormone replacement therapy.


Q: Why might a doctor switch a patient from an oral steroid to Solu Cortef?

A: The injectable form is indicated for use when a patient is in an acute, severe medical crisis and oral therapy is not feasible. This is necessary when high blood levels of the active ingredient are needed rapidly or when the patient cannot take or absorb medication effectively by mouth due to their condition.


Q: Does Solu Cortef contain lactose or gluten?

A: Official manufacturer information lists Solu Cortef for injection as being Gluten Free. The composition of the sterile powder for injection does not typically include lactose as an excipient.


Q: Who should not receive treatment with Solu Cortef?

A: Official regulatory documents state that the drug is contraindicated in patients who have an active systemic fungal infection or a known hypersensitivity (allergy) to the product. It is also forbidden for administration into the spine (intrathecal) or near the spinal cord (epidural).


Q: Does official research support the use of Solu Cortef in all its listed conditions?

A: Official product information confirms the medication's use across various indications, which is supported by its established anti-inflammatory and hormonal properties. Studies have demonstrated its rapid onset and effectiveness in managing acute episodes requiring immediate intervention.


Q: Are there specific warnings for people with heart conditions?

A: Yes, official warnings advise that Solu Cortef should be used with significant caution in patients with certain heart conditions. This includes patients with congestive heart failure and high blood pressure, due to the potential risk of fluid retention and loss of potassium associated with corticosteroid use.


Q: Are there specific storage requirements for the Solu Cortef vials after mixing?

A: Official guidelines state that once the powder is mixed with the liquid (reconstituted), the solution must be stored at controlled room temperature (20 C to 25 C) and protected from light. If not used immediately, the solution must be discarded within 12 hours if kept at room temperature, or after 24 hours if refrigerated.

How should Solu Cortef be stored and disposed of?

Solu-Cortef Storage and Disposal Instructions

Storage Conditions

Solu-Cortef (hydrocortisone sodium succinate) sterile powder must be stored at Controlled Room Temperature (20 C to 25 C). The powder must be kept in its original container and protected from light until use.

Stability After Preparation

Once reconstituted, the solution should be used promptly. If not used immediately, the solution must be stored at Controlled Room Temperature and discarded after 3 days.

Handling and Safety

For safety, the medication must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired Solu-Cortef must be disposed of in accordance with local regulatory requirements. Needles and syringes (sharps) must be placed immediately into an FDA-cleared sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solu Cortef found in:

A-Z Index: